India's best angioplasty surgeons have accelerated the window for endovascular stroke therapy from 6 to 24 hours, providing the choice of treating more ischemic stroke patients.
For Consultation
International Helpline Number : +91-9370586696
Email id: enquiry@indiacardiacsurgerysite.com
Dr. Vipul Gupta India also researches new therapies, such as stem cell therapy for stroke. You can rely on the best interventional neurologist in Delhi India for comprehensive care, from lifesaving stroke and infarct care from you from diagnosis through recovery, ensuring you maintain great neurological health.
The stroke program by Dr. Vipul Gupta brings collectively leading professionals in vascular neurology, neurosurgery, neurocritical care, neuro-interventional radiology, neuroradiology medicine that focus on diagnosing and treating people with disorders affecting vessels of the brain and spinal cord.
Only abstract available here. Supra-physiologic Testosterone therapy needs to be included in potential causes of polycythemia and stroke in men. Remember the 25-50-21 rule in that 25% of men on Testosterone therapy are never checked prior to initiation of Testosterone and 50% are not followed after initiation of Testosterone therapy.
nice review, older, of ischemic stroke risk and ways to prevent/heal in a more integrative approach. Good review of risk associated with hs-CRP and homocysteine as well.
Vitamin B12, methyl cobalamin, is very important in lowering homocysteine levels through methionine synthase. The VISP trial did not show efficacy in the intention to treat analysis. However, analysis of the efficacy reveals that many clients had too low of vitamin B12 levels due to malabsorption and vitamin B12 levels should have been higher in the VISP intention to treat.
Vitamin B12, B6, and folic acid shown to lower homocysteine levels and decreased the incidence of stroke. However, overall mortality and CVD deaths were not.
This is a short interview of the author on a recent retrospective review that revealed no increase in cardiovascular events in men. The author rightly points out his data, which is quite different than the previous JAMA and PLOSone publications which showed an increase in cardiovascular events.
However, the lead author points out the main problem with comparisons: his study group was younger and healthier. So, the comparison is apples to oranges. Studies still point to increased risk of Testosterone therapy in men with pre-existing CVD. This new study does not refute this point at all.
Another serious flaw here, is that only Testosterone was followed. This logic is seriously flawed as I have previously documented. The author points out the flaw in the levels in the JAMA study post treatment. But he fails to account for the the lack of adequate pathway assessment i.e.aromatazation. Also, no inflammatory cytokine evaluation was performed in that study. Both of these should have been highlighted.
In contrast, a positive was the length of follow.
Study of Iraqi population at elevated risk of stroke found that both serum and salivary levels of malondialdehyde, glutathione, superoxide dismutase, and uric acid proved useful as potential biomarkers of risk assessment.
progesterone shown to provide substantial reduction in volume of infarct in rat stroke model. This is very promising, and with with other studies revealing the same benefit in the human brain, progesterone should become a part of initial treatment in those with acute brain injuries and should be evaluated for those with aging diseases of the brain.
progesterone shown to have neuroprotective and healing properties in the CNS. This has implications in Stroke, and possibly even excitotoxic disease such as Parkinson's, Alzhemier's...